EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inmunoterapia en el mieloma múltiple

Pedro Asensi Cantó, Mario Arnao Herraiz, Javier de la Rubia Comos

Medicina Clínica · 2024

DOI: 10.1016/j.medcli.2023.11.019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicina Clínica, 2024. Verfasst von Pedro Asensi Cantó und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Immunotherapy. Die Arbeit nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with multiple myeloma who present with refractory disease or relapse after receiving the main classes of available drugs -immunomodulators, proteasome inhibitors and antibodies against CD38- do not have satisfactory therapeutic alternatives. New treatments based on the redirection of T lymphocytes to act directly against tumor cells, such as bispecific antibodies and T cells with chimeric antigen receptors, are changing this scenario. The published information confirms unprecedented antitumor activity of these agents in patients with refractory myeloma and they will certainly represent the backbone of the treatment of these patients in the immediate future. However, these therapies also present specific characteristics and medium or long-term toxicities that pose new healthcare challenges. In this review, we address the current results and future challenges of the administration of these treatments in patients with relapsed or refractory multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificImmunotherapyHumansReceptors, Chimeric AntigenImmunotherapy, AdoptiveAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Anticuerpo biespecíficoBispecific antibodyCAR-T cellsCélulas CAR-TImmunotherapyInmunoterapiaMieloma múltipleMultiple myeloma

Substanzen

Antibodies, BispecificReceptors, Chimeric AntigenAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España.
  • Servicio de Hematología y Hemoterapia, Hospital Universitario y Politécnico La Fe, Valencia, España; Facultad de Medicina y Odontología, Universidad Católica de Valencia, Valencia, España; Instituto de Investigación San…

Zitieren

APA

Asensi Cantó, P., Arnao Herraiz, M., & de la Rubia Comos, J. (2024). Inmunoterapia en el mieloma múltiple. Medicina Clínica. https://doi.org/10.1016/j.medcli.2023.11.019

Vancouver

Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J. Inmunoterapia en el mieloma múltiple. Medicina Clínica. 2024. doi:10.1016/j.medcli.2023.11.019

BibTeX
@article{AsensiCant2024,
  author = {Asensi Cantó, Pedro and Arnao Herraiz, Mario and de la Rubia Comos, Javier},
  title = {Inmunoterapia en el mieloma múltiple},
  journal = {Medicina Clínica},
  year = {2024},
  doi = {10.1016/j.medcli.2023.11.019}
}
Kostenlos starten →